Clearmind Medicine Inc. (NASDAQ: CMND) reported that the second cohort of its FDA‑approved Phase I/IIa study of CMND‑100, an oral MEAI‑based therapy for alcohol use disorder, has finished treating all six enrolled patients. The cohort was run at three leading clinical sites—Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center—highlighting the company’s multinational trial footprint and the strong interest from top research institutions.
The completion of the second cohort confirms the safety and tolerability profile that was established in the first cohort and positions Clearmind to move forward with the next data readout. A full safety and pharmacokinetic analysis will be released in the coming months, and the results will inform the design of subsequent cohorts and the company’s regulatory strategy for CMND‑100.
CEO Dr. Adi Zuloff‑Shani said the milestone “reflects the dedication of our clinical sites and the strong interest in CMND‑100 as a potential innovative therapy for AUD, a condition with significant unmet medical needs.” The comment underscores the company’s confidence that the drug’s safety profile will support accelerated development and eventual regulatory approval.
CMND‑100 targets a large global market for alcohol use disorder, where current FDA‑approved treatments—disulfiram, naltrexone, and acamprosate—offer limited efficacy. By demonstrating a favorable safety profile in a multinational cohort, Clearmind strengthens its position to attract additional investment, expand clinical development, and potentially capture a meaningful share of the AUD treatment market.
The company expects to release topline data from the second cohort in the next few months, after which it will evaluate the results to determine the optimal dosing strategy and plan for Phase III studies. The data readout will be a key indicator of the drug’s clinical trajectory and will influence the company’s regulatory and commercialization roadmap.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.